AAP
ENTA icon

Arax Advisory Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Arax Advisory Partners’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.14K Buy
90
+84
+1,400% +$1.13K ﹤0.01% 3261
2025
Q4 		$95 Sell
6
-7,756
-100% -$98.5K ﹤0.01% 3833
2025
Q3 		$92.9K Buy
+7,762
New +$62K ﹤0.01% 1564
2024
Q4 		– Sell
-128
Closed -$1.33K – 2517
2024
Q3 		$1.33K Hold
128
– – ﹤0.01% 2174
2024
Q2 		$1.66K Buy
+128
New +$1.73K ﹤0.01% 2024

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arax Advisory Partners's ENTA Position: Q1 2026 in Review

Arax Advisory Partners increased its Enanta Pharmaceuticals (ENTA) stake by 1,400% in Q1 2026, buying an estimated $1.13K and bringing the position to 90 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #3261.

Arax Advisory Partners first reported a position in ENTA in Q2 2024 and has held it in 5 quarters since. The position peaked at $92.9K in Q3 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Arax Advisory Partners held 90 shares of Enanta Pharmaceuticals worth $1.14K as of Q1 2026.
  • Arax Advisory Partners bought 84 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1.13K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3261 holding.
  • Arax Advisory Partners first reported a position in Enanta Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Enanta Pharmaceuticals position peaked at $92.9K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.